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 ELECTRONIC POSTER: CLINICAL TRACK: HEALTH 
ECONOMICS  
  
EP-1126 
FMEA application to prevent clinical risk in radiotherapy 
A. Fozza1, E. Cazzulo1, L. Berretta1, M.P. Barbero1, A. Orecchia1, G. 
Pozzi1, P. Franzone1 
1A.O. SS. Antonio e Biagio e Cesare Arrigo, Radiation Oncology, 
Alessandria, Italy  
 
Purpose/Objective: Aim of our work was the implementation of FMEA 
(Failure mode and effects analysis). We used the FMEA in the analysis 
of the process: 'Radiotherapy Treatment', to identify possible errors, 
consequent effects of them, and to apply improvement suggestions of 
risk reduction. 
Materials and Methods: At the beginning of 2010, at our Radiotherapy 
Department, a risk management dedicated working group was set up. 
'Radiotherapy treatment' was the process chosen for the analysis, i.e. 
the patient’s course since the first radiotherapy session till the 
treatment’s end. All the different failure modes, requiring 
containment actions, were identified and ranked, based on severity 
(S), occurrence probability (OP), and probability that this particular 
failure would go undetected (D). Each event was rated to assign a risk 
probability numbers (RPN), in terms of severity according to Technical 
Commission of Risk Management scale, and in terms of probability of 
occurrence and failure according to the JCHAO modified scale, each 
one on a scale of 1 to 5. The RPN for each failure mode has been 
identified on a tabulated scores multiplying together the three value 
of S, OP and D parameters. Before we analyzed a total of 19 different 
failure modes, and after we reported the RPN for each event in a 
prioritization matrix divided into risk classes (low, intermediate and 
high risk). Finally for each failure modes we studied its containment 
action to be applied to RPN to decrease the risk class. 
Results: In our work the seven failure modes, classified in the high 
risk prioritization matrix, were considered for interventional 
solutions. The activities were: 1) lack of notes for electron treatments 
for head and neck cancer, 2) wrong phase sequence planning after 
treatment stop, 3) exchange of patients at the waiting room call, 4) 
lack of EPID control, 5) missing control request for the EPID by the 
technician, 6) collision between the Linac gantry and the patient, 7) 
lack of planning for the visits during therapy. The containment actions 
for each failure mode were respectively: 1) reductions in the usage of 
phases with electrons, 2) planning of one phase at a time, 3) delivery 
of identification badge, sporting name, surname and treatment sheet 
number, to show before each session, 4) annotation by the radiation 
oncologist of all verifications to repeat, 5) double check by the 
technicians that the EPID control was requested, 6) test of all fields 
during the first session, with added explanation notes, 7) planning on 
an electronic calendar of the visits during the therapy. With the 
application of the containment action we obtained a significant 
reduction of the risk factor score in all the failure modes considered.  
Conclusions: All identified containment actions were introduced by 
December 2011. At the end of 2012 their efficacy will be measured, 
by re-evaluation of all indexes based on the occurrences during the 
year. 
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Purpose/Objective: The median age in India in 2012 is 26.5 (male 
25.9 and female 27.2) where as the life expectancy has grown to 
67.14 (male 66.08 and female 68.33). Life expectancy was 31 in 1947, 
the year India got Independence. With increased life expectancy 
cancer incidence is on the rise. Healthcare delivery in India has 
witnessed a sea change in the new millennium. Oncology, especially 
radiation oncology has made quantum jumps, by way of acquisition of 
high tech and expensive equipment. A country with a population 
touching 1.25 billion and now among the top 4 economies of the world 
India has the potency for many more high end technologies including 
Particle and Proton therapy facilities. A study of the growth of 
radiotherapy technology in India in the new millennium is done. 
Materials and Methods: India with its colonial history has traditionally 
been a low-tech and manpower intensive healthcare provider. The 
new millennium however has brought the new era of reforms and 
economic development. Recent infusion of technology across the 
country and paradoxical abilities of making such technologies 
economically viable in all major disciplines of medicine, be it Cardiac 
Care or Robotic Surgeries, is noteworthy. In radiotherapy there is 
several fold addition of equipment with capabilities like 3D CRT, 
IMRT, IGRT, Stereotactic Body Radiotherapy, Robotic Radiosurgery and 
Helical Tomotherapy in several centers in various parts of India. The 
data and trends of growth of each of these technologies in India is 
studied.  
Results: India had its first linear accelerator in 1982 and had its first 
linear accelerator based dedicated stereotactic radiosurgery in 1996, 
The total number of linear accelerators remained in single digit till 
2000.The first IMRT was delivered in 2001, but the lag between 
technology adoption narrowed significantly in the later part of the 
decade. Linear Accelerators grew from 22 in early 2002 to 237 by 
March 2012, an impressive growth of more than 1000% in a decade. 
Cobalt units have reduced from 258 in 2003 to 237 in 2012 and many 
more are being decommissioned. HDR brachy therapy units have 
grown from 50 in 2003 to 200 in 2012, a fourfold increase. The same is 
true in diagnostic facilities like the PET-CT scanners and 3T MRI and 
related equipment. With highly acclaimed competencies in core 
scientific communities in the field of Nuclear Physics and Nuclear 
Engineering in place, it is very likely that India will have its own 
particle therapy facility in this decade itself. 
Conclusions: The acquisition of high-end equipment in radiotherapy in 
India is significant both quantitatively and qualitatively. India is 
known for its scientific achievements in atomic energy, space 
sciences, satellite communication, missile technology and information 
technology (IT). The current trend certainly gives India an edge in 
healthcare too.The gap of accessibility and affordability however is 
there and is beyond the purview of the current study. The 
transformation of Indian health care is real and radiotherapy in India 
is all set to achieve new heights. 
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Purpose/Objective: The radiodermatitis is the most frequent reaction 
during the accomplishment of external beem radiotherapy. Clinicaly 
radiodermatitis is manifested with appearance of erythema, dry and 
moist desquamation. Its prevention and treatment are necessary for 
the aim of accomplishing the planned therapeutic dose. 
Materials and Methods: In the Clinic of Radiotherapy within the 
National Hospital of Oncology for the period March – July 2012, 
prevention and treatment was carried out of acute radiodermatitis 
with Water Jel R1 and R2 on 30 patients. In 27 of the cases, the 
preparations were applied after the appearance of the radiodermatitis 
1st degree as per CTCAE v. 4. This usually occurs after realization 
oftotal dose of 30-36Gy, and in 3 of the patients for prevention from 
radiodermatitis from the beginning to the end of the radiotherapy. 
The patients from the first group suffer from carcinoma in the head 
and neck area and are undergoing definitive radiotherapy or chemo-
radiotherapy treatment, the three patients from the second group - 
carcinoma in the mammary gland and undergoing postoperative 
radiotherapy. 
Results: Affecting the symptoms of the radiodermatitis, such as pain, 
dryness and erythema has been observed immediatly after the first 
application of the two products Water Jel R1 and R2. 
In two of the patients with carcinoma in head and neck, after the 
application of the preparations, the realization of surdosage for the 
field of the primary tumor up to 70Gy became possible, without 
discontinuing the radiotherapy after 60 Gy. In patients for whom 
preventive treatment has been performed with Water Jel R1 andR2 
appearance of radiodermatitis 1st degree was not observed at all, but 
only slight pigmentation at the end of the radiotherapy. 
Conclusions: The application of the two preparations Water Jel R1 
and R2 is: easy and convenient for the patients, as the subjective 
complaints are being influenced (such as pain, dryness and erythema) 
as well as the comfort during the radiotherapy is improved. The 
improvement of the tolerance towards the treatment is present and at 
the same time the discontinuation due to appearance of 
radiodermatitis of 2nd and 3rd degree is avoided, whereas no side 
effects are observed. In the clinical practice these preparations can 
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successfully be used for prevention and treatment of acute 
radiodermatitis.  
   
EP-1129   
Radiotherapy for mucosa-associated lymphoid tissue lymphoma of 
the ocular adnexa 
Y. Monzen1 
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Purpose/Objective: Radiotherapy is useful for the treatment of MALT 
lymphoma of the ocular adnexa and is the first choice for this disease. 
We investigated the long-term follow-up results of radiotherapy for 
MALT lymphoma of the ocular adnexa. 
Materials and Methods: Twenty-four patients with MALT lymphoma of 
the ocular adnexa were treated with radiotherapy alone. The disease 
arose from the conjunctiva in 18 patients (10 with bilateral 
involvement), and from the retrobulbar space in 6 patients (1 with 
bilateral involvement). The median follow-up of the surviving patients 
was 70 months (range, 6-157). The histological diagnoses obtained via 
an incisional biopsy in all cases were categorized according to the 
criteria established by the WHO classification. During the staging 
work-up, gallium scans, computed tomography of the chest and 
abdomen, and FDG-PET were performed for all patients. Patients with 
IAE or IAE2 disease according to the American Joint Committee on 
Cancer TNM Classification were treated with radiotherapy alone. 
Lesions confined to the conjunctiva were treated with a single 
anterior direct field using a 6-12 MeV electron beam. The entire 
bulbar and palpebral conjunctiva were treated. Retrobulbar tumors 
were irradiated with 18 MeV electron or 6-MV X-rays. The clinical 
target volume was the entire orbital cavity. A median dose per 
fraction of 2.0Gy (range 1.8-2.5) was administered, with the total 
dose ranging between30 and 54Gy (median, 38Gy). Lead eye shields 
were used for radiotherapy of conjunctival lymphoma. Lens protection 
was not used for radiotherapy of retrobulbar lymphoma except for one 
patient.  
Results: All patients with MALT lymphoma achieved a CR or 
unconfirmed CR (CRu). Two patients died of other disease.  
One patient died of lung cancer and another patient died of 
progressive supranuclear palsy. The 5-and 10-year overall survival 
rates of all patients with MALT lymphoma were 100% and 90%, 
respectively. The 5-and 10-year cause-specific survival rates were 
100% and 100%, respectively. Seven eye-balls developed delayed 
toxicity. Four eye-balls with conjunctival lymphoma experienced dry 
eye syndrome, and four eye-balls developed cataracts. One patient 
with retrobulbar lymphoma experienced both dry eye syndrome and 
cataracts. The vision of patients with cataracts was restored by 
surgery. In seven eye-balls, the radiation dose had been 40Gy or 
more.  
Conclusions: Excellent local control and survival can be achieved for 
patients with MALT lymphoma of the ocular adnexa using radiotherapy 
alone. As a dose of more than 30Gy develops dry eye syndrome or 
cataract, the dose must not exceed 30Gy for safe treatment of MALT 
lymphoma of the ocular adnexa. At present, based on our study and 
previous studies, we administer a radiation dose of 30.6Gy with a 
fraction size of 1.8Gy for MALT lymphoma of ocular adnexa treatment. 
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Purpose/Objective: The presence of an air filled ionization chamber 
in a surrounding medium introduces several fluence perturbations in 
high energy photon and electron beams which have to be accounted 
for. One of these perturbations, the displacement effect, may be 
corrected in two different ways: by a correction factor pdis or by the 
application of the concept of the effective point of measurement 
(EPOM). The latter means, that the volume averaged ionization within 
the chamber is not reported to the chambers reference point but to a 
different point, the so called effective point of measurement.  
Materials and Methods: Within this study the EPOM was determined 
for four different parallel plate and two cylindrical chambers in mega 
voltage electron beams using Monte Carlo simulations. The positioning 
of the chambers with this EPOM at the depth of measurement results 
in a largely depth independent residual perturbation correction.  
Results: For all parallel plate chambers the EPOM is independent on 
the energy of the primary electrons. Whereas for the Advanced Markus 
chamber the position of the EPOM coincides with the chambers 
reference point, it is shifted for the other parallel plate chambers 
several tenths of millimeters downstream the beam direction into the 
air filled cavity. For the cylindrical chambers there is an increasing 
shift of the EPOM with increasing electron energy. This shift is in 
upstream direction, i.e. away from the chambers reference point 
toward the focus. For the highest electron energy the position of the 
calculated EPOM is in fairly good agreement with there commendation 
given in common dosimetry protocols, for the smallest energy the 
calculated EPOM positions deviates about 30% from this 
recommendation.  
Conclusions: Besides the determination of the EPOM, the residual 
perturbation correction for all investigated chambers for the whole 
range of clinical used electron energies was calculated. The 
application of the proposed effective point of measurement will 
increase the accuracy of calculating depth dose data from measured 
depth ionization curves, especially for depth beyond the reference 
depth. 
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Purpose/Objective: Modulated arc therapy is becoming the common 
technique to deliver Stereotactic Radiotherapy. A double challenge 
arises with respect to its verification. Not only a dose plane should be 
measured but preferably the entire 3D dose distribution. And, since it 
includes steep gradient regions, this dose distribution should be 
obtained with a spatial resolution as high as possible. The aim of this 
study is to commission a new system which facilitates this procedure, 
and to evaluate the routine use of this new measuring device. 
Materials and Methods: Recently, a new approach to the measure of 
the 3D dose distribution arised with the introduction of the new 
Octavius 4D system (PTW). It consists of an ion chamber array 
embedded in a cylindrical phantom. The phantom is connected to an 
inclinometer that is attached to the gantry, so that the system is 
capable to rotate following the gantry orientation in such a way that 
the array is always perpendicular to the beam axis. Dose distribution 
and gantry angle are registered as a function of time. Provided with a 
set of percentage depth dose curves, previously measured and 
introduced in the system software, the system computes the dose 
distribution for each gantry angle and reconstructs the resulting 3D 
dose matrix. The system allows several options for the ion chamber 
array: the well-known 2D-Array seven29; its successor Octavius 
Detector 729; or the small field dedicated Octavius 1000 SRS array, 
which was used in this study, with 977 liquid filled, 2.3×2.3×0.5 mm3 
sized ion chambers covering a 11×11 cm2 area, with a 2.5 mm spacing 
in the central 5.5×5.5 cm2 region. The accelerators used were Varian 
Clinac iX and Varian TrueBeam with MLC 120HD. The TPS was Eclipse 
(version 10.0). The commissioning measurements consisted of the 
following tests: (1) Homogeneity of chamber response evaluated as 
the maximum deviation with respect to the mean for a uniform field; 
(2) Linearity, evaluated by fitting measured dose versus UM with a 
linear function; (3) Reproducibility, evaluated as the maximum 
difference between several measures with respect to the mean, for 
the same UM value; (4) Leakage current, pre- and post-irradiation; (5) 
Verification of typical SBRT clinical plans, evaluated by comparing 
TPS-calculated versus measured dose using 3D gamma index, with 3%, 
3 mm criteria. 
Results: (1) The homogeneity between chambers was 0.8%. (2) 
Linearity was found to be excellent, with an r2 value better than 
0.999. (3) The reproducibility was found to be 0.08%. (4) Leakage 
increases with previously measured dose and shows its largest 
variation for large fields. For a 10×10 cm2 field, it ranges from –0.35 
cGy/h to 1.18 cGy/h. (5) Verification of typical clinical plans showed 
a mean pass ratio of 94.6% (range 91.8%-96.4%). 
Conclusions: Octavius 4D system together with Octavius 1000 SRS 
array is an adequate tool in the routine patient-specific QA of SBRT 
VMAT IMRT treatment plans. 
 
